Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy

Lung Cancer

Volumn 71, Issue 1, 2011, Pages 75-81

  Bölükbas, Servet ^a   Manegold, Christian ^b   Eberlein, Michael ^c   Bergmann, Thomas ^a   Fisseler Eckhoff, Annette ^a   Schirren, Joachim ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Malignant pleural mesothelioma; Radiation; Radical pleurectomy; Surgery

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED;

ACUTE ABDOMEN; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOTHORAX; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURA MESOTHELIOMA; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURECTOMY; PNEUMOTHORAX; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; WOUND INFECTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEASIBILITY STUDIES; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; THORACOTOMY;

EID: 78650227719     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.08.019     Document Type: Article

References (26)

1. Merritt N., Blewett C.J., Miller J.D., Bennett W.F., Young J.E., Urschel J.D. Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 2001, 78:171-174.
2. Sugarbaker D.J. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol 2006, 1(February (2)):175-176.
3. Martini N., Bains M.S., Beattie E.J. Indications for pleurectomy in malignant effusion. Cancer 1975, 35(March (3)):734-738.
4. Nakas A., Trousse D.S., Martin-Ucar A.E., Waller D.A. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg 2008, 34(October):886-891.
5. Boutin C., Rey F., Viallat J.R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 1995, 108(September):754-758.
6. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma. The International Mesothelioma Interest Group. Chest 1995, 108:1122-1128.
7. Weder W., Stahel R.A., Bernhard J., Bodis S., Vogt P., Ballabeni P., et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007, 18(July):1196-1202.
8. Flores R.M., Pass H.I., Seshan V.E., Dycoco J., Zakowski M., Carbone M., et al. Extrapleural pneumonectomy versus pleurectomy in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008, 135(March):620-626.
9. de Perrot M., Feld R., Cho B.C.J., Bezjak A., Anraku M., Burkes R., et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27(March):1413-1418.
10. Rusch V.W., Venkatraman E.S. Important prognostic factors in patients with malignant pleural mesothelioma managed surgically. Ann Thorac Surg 1999, 68(November):1799-1804.
11. Butchart E.G., Ashcroft T., Barnsley W.C., Holden M.P. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976, 31(February):15-24.
12. Sugarbaker D.J., Jaklitsch M.T., Bueno R., Richards W., Lukanich J., Mentzer S.J., et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004, 128(July):138-146.
13. Schipper P.H., Nichols F.C., Thomse K.M., Deschamps C., Cassivi S.D., Allen M.S., et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008, 85(January):257-264.
14. Lucchi M., Chella A., Melfi F., Dini P., Ambrogi M., Fino L., et al. A phase II study of intrapleural immuno-chemotherapy, pleurectomy, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg 2007, 31(March):529-534.
15. Richards W.G., Zellos L., Bueno R., Jaklitsch M.T., Jänne P.A., Chirieac L.R., et al. Phase I to II study of pleurectomy and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006, 24(April):1561-1567.
16. Lee T.T., Everett D.L., Shu H.G., Jahan T.M., Roach M., Speight J.L., et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2002, 124(December):1183.
17. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., Richards W.G., Strauss G.M., Corson J.M., et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117(January):54.
18. Krug L.M., Pass H.I., Rusch V.W., Kindler H.L., Sugarbaker D.J., Rosenzweig K.E., et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27(June):3007-3013.
19. Manegold C., Symanowski J., Gatzemeier U., Reck M., von Pawel J., Kortsik C., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005, 16(June):923-927.
20. Averbach A.M., Sugarbaker P.H. Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res 1996, 81(January):193-211.
21. Rusch V.W., Rosenzweig K., Venkatraman E., Leon L., Raben A., Harrison L., et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001, 122(October):788.
22. Gupta V., Mychalczak B., Krug L., Flores R.M., Bains M., Rusch V.W., et al. Hemithoracic radiation therapy after pleurectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005, 63(4):1045-1052.
23. Metintas M., Ak G., Parspour S., Yildirim H., Erginel S., Alatas F., et al. Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma. Lung Cancer 2008, 61(August (2)):255-261.
24. Lee C, Bayman N, Swindell R, Faivre-Finn C. Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice. Lung Cancer, July 2009; doi:10.1016/j.lungcan.2009.06.014.
25. Munter M.W., Nill S., Thilmann C., Hof H., Hoss A., Haring P., et al. Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma. Feasibility and initial results. Strahlenther Onkol 2003, 179(August (8)):535-541.
26. Branscheid D., Krysa S., Bauer E., Bulzebruck H., Schirren J. Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardiothorac Surg 1991, 5(July):466-472.